Meridian Bioscience Inc. (NASDAQ:VIVO) headquartered in Cincinnati, will host a conference call for the investment community to discuss the 4Q20 earnings result on 13th November 2020 at 10:00 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.meridianbioscience.com
Individuals interested in participating in the audio call may dial the listen only number(s) (866) 443-5802 U.S. or (513) 360-6924 (International), with passcode : 3958286
Earnings Expectation
Meridian Bioscience Inc. is expected to report fourth quarter earnings results, before market open, on Friday 13th November 2020. Analysts polled by Thomson Reuters anticipate fourth quarter income of $ 0.14 per share from revenue of $ 59.64 million. Looking ahead, the full year income are expected at $ 1.02 per share on the revenues of $ 249.15 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 245.00 million ~ $ 250.00 million, where as bottomline are predicted in a range of $ 1.01 ~ $ 1.05 per share
Click Here For More Historical Outlooks Of Meridian Bioscience Inc.
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the Alethia brand; rapid immunoassays, a single-use immunoassays under the ImmunoCard and ImmunoCard STAT!
